Dean Rudge
Deputy Editor
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
The Separation Of Sandoz, A Story Years In The Making
Novartis’ shareholders last month voted yes on the proposal to separate Sandoz into a standalone generics and biosimilars firm. On the eve of the spin-off, Generics Bulletin looks back at a deal that was seemingly destined to happen sooner rather than later.
What’s Next? Five Things To Look Out For In October
Generics Bulletin previews the most notable and anticipated events for October 2023.
Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.
US Court Says Yes To Gilead’s Quarter Billion Dollar Settlement On Truvada, Atripla
Despite winning a landmark multi-billion-dollar antitrust suit earlier this year, Gilead Sciences has seen a US court give an initial green light allowing it to shell out nearly $250m to settle antitrust claims from direct purchasers of its two major HIV drugs.
Vanda Sues FDA For ‘Cutting Corners’ On MSN’s Generic Hetlioz Approval
Looking to take the FDA to court again, Vanda Pharmaceuticals has sued the agency for the way in which it evaluated and approved MSN Pharmaceuticals’ generic version of its sleep-wake disorder drug Hetlioz.
Rani Takes Next Step As Oral Ustekinumab Biosimilar Enters The Clinic
As biosimilars to Stelara (ustekinumab) continue to advance in global markets, Rani Therapeutics has made progress for its proposed RT-111 orally administered ustekinumab biosimilar.